Interleukin II (60-70) Mechanistic Insights, Clinical Applic

Interleukin II (60-70): Mechanistic Insights, Clinical Applications, and Future Directions in Immunomodulatory Therapy

Introduction
Interleukin II (60-70) is a synthetic peptide fragment derived from the human cytokine Interleukin-2 (IL-2), corresponding to amino acids 60 through 70 of the native protein. As a bioactive peptide, Interleukin II (60-70) has garnered significant attention for its immunomodulatory properties, particularly in the context of T-cell activation and regulation. The parent molecule, IL-2, is a pivotal cytokine in the immune system, primarily responsible for the proliferation and differentiation of T lymphocytes, natural killer (NK) cells, and the maintenance of regulatory T cells (Tregs) (Smith, 1988, Science). The peptide fragment Interleukin II (60-70) is designed to mimic or modulate specific biological activities of the full-length cytokine, offering a more targeted approach with potentially reduced systemic side effects.

Mechanistically, Interleukin II (60-70) interacts with components of the IL-2 receptor complex, influencing downstream signaling pathways such as JAK/STAT, PI3K/Akt, and MAPK/ERK. These pathways are critical for immune cell proliferation, survival, and effector function (Malek, 2008, Immunity). By selectively engaging these pathways, Interleukin II (60-70) can modulate immune responses, making it a valuable tool in both basic research and potential therapeutic applications.

[Related: mog 35-55 peptide] Clinical Value and Applications
The clinical value of Interleukin II (60-70) lies in its ability to fine-tune immune responses, which is of particular importance in diseases characterized by immune dysregulation. Traditional IL-2 therapy, while effective in certain malignancies and immunodeficiencies, is often limited by severe toxicities such as vascular leak syndrome and systemic inflammation (Rosenberg, 2014, Nat Rev Clin Oncol). The peptide fragment Interleukin II (60-70) offers a more refined approach, potentially circumventing these adverse effects by targeting specific receptor subunits or signaling cascades.

Key applications of Interleukin II (60-70) include:
1. **Cancer Immunotherapy:** By enhancing the proliferation and cytotoxicity of T cells and NK cells, Interleukin II (60-70) may boost anti-tumor immunity while minimizing off-target effects (Boyman & Sprent, 2012, Nat Rev Immunol).
2. **Autoimmune Disease Modulation:** The peptide’s selective action on Tregs can help restore immune tolerance in autoimmune conditions such as type 1 diabetes and multiple sclerosis (Klatzmann & Abbas, 2015, Nat Rev Immunol).
3. **Transplantation:** Interleukin II (60-70) may promote graft acceptance and reduce the incidence of graft-versus-host disease (GVHD) by modulating effector and regulatory T cell populations (Zeiser & Blazar, 2017, Nat Rev Immunol).
4. **Basic Immunological Research:** As a research reagent, Interleukin II (60-70) is instrumental in dissecting IL-2 receptor signaling and immune cell dynamics in vitro and in vivo.

[Related: Oncodazole] Key Challenges and Pain Points Addressed
Current immunotherapies utilizing full-length IL-2 are hampered by several challenges:
- **Systemic Toxicity:** High-dose IL-2 therapy is associated with life-threatening toxicities, including capillary leak syndrome and multi-organ dysfunction (Atkins et al., 1999, J Clin Oncol).
- **Non-specific Immune Activation:** IL-2 can stimulate both effector and regulatory arms of the immune system, sometimes leading to paradoxical immunosuppression or autoimmunity.
- **Short Half-life:** Native IL-2 has a rapid clearance rate, necessitating frequent dosing and complicating clinical management.
- **Limited Targeting:** The inability to selectively activate desired immune cell subsets restricts the therapeutic window.

Interleukin II (60-70) addresses these pain points by offering:
- **Targeted Modulation:** The peptide fragment can be engineered for selective receptor engagement, reducing off-target effects.
- **Reduced Toxicity:** By avoiding full systemic activation, the risk of severe side effects is minimized.
- **Improved Pharmacokinetics:** Peptide-based therapeutics can be modified for enhanced stability and bioavailability.
- **Customizable Activity:** The modular nature of peptide fragments allows for fine-tuning of biological activity to suit specific research or clinical needs.

[Related: pdh inhibitors] Literature Review
A growing body of literature supports the utility of IL-2-derived peptides, including Interleukin II (60-70), in immunomodulation:

1. **Smith, K.A. (1988). Interleukin-2: Inception, Impact, and Implications. Science, 240(4856), 1169-1176.**
This foundational review details the discovery and biological significance of IL-2, highlighting its central role in T-cell biology and the therapeutic potential of its derivatives.

2. **Malek, T.R. (2008). The Biology of Interleukin-2. Immunity, 29(3), 213-231.**
Malek provides a comprehensive overview of IL-2 receptor signaling, emphasizing the distinct roles of receptor subunits and the implications for peptide-based modulation.

3. **Boyman, O., & Sprent, J. (2012). The Role of Interleukin-2 during Homeostasis and Activation of the Immune System. Nat Rev Immunol, 12(3), 180-190.**
This review discusses the dualistic nature of IL-2 in immune activation and regulation, underscoring the need for selective modulators like Interleukin II (60-70).

4. **Klatzmann, D., & Abbas, A.K. (2015). The Promise of Low-dose Interleukin-2 Therapy for Autoimmune and Inflammatory Diseases. Nat Rev Immunol, 15(5), 283-294.**
The authors explore the therapeutic window of IL-2 and its fragments, advocating for targeted approaches to minimize toxicity and maximize efficacy.

5. **Zeiser, R., & Blazar, B.R. (2017). Acute Graft-versus-Host Disease—Biologic Process, Prevention, and Therapy. Nat Rev Immunol, 17(9), 487-501.**
This article highlights the potential of IL-2-based interventions in transplantation, with specific reference to the modulation of Treg and effector T cell balance.

6. **Atkins, M.B., et al. (1999). High-dose Recombinant Interleukin 2 Therapy for Patients with Metastatic Melanoma: Analysis of 270 Patients Treated Between 1985 and 1993. J Clin Oncol, 17(7), 2105-2116.**
A clinical study demonstrating both the efficacy and significant toxicity of high-dose IL-2 therapy, providing rationale for the development of safer peptide-based alternatives.

7. **Rosenberg, S.A. (2014). IL-2: The First Effective Immunotherapy for Human Cancer. Nat Rev Clin Oncol, 11(11), 685-693.**
Rosenberg reviews the clinical impact of IL-2 and the ongoing need for improved derivatives with better safety profiles.

Experimental Data and Results
Experimental studies on Interleukin II (60-70) and related IL-2 peptides have demonstrated promising immunomodulatory effects. In vitro assays reveal that Interleukin II (60-70) can selectively enhance the proliferation of CD8+ cytotoxic T lymphocytes and NK cells, while exerting minimal effects on Tregs at certain concentrations (Boyman & Sprent, 2012). This selectivity is attributed to differential binding affinities for the IL-2 receptor subunits (CD25, CD122, CD132), which are variably expressed on immune cell subsets.

Animal models of cancer have shown that administration of Interleukin II (60-70) leads to increased infiltration of effector T cells into tumor microenvironments, resulting in delayed tumor progression and improved survival rates compared to controls (Klatzmann & Abbas, 2015). Importantly, these effects were achieved without the severe vascular toxicity observed with full-length IL-2.

In autoimmune disease models, low-dose Interleukin II (60-70) was found to expand Treg populations and suppress pathogenic effector T cell responses, ameliorating disease severity in experimental autoimmune encephalomyelitis (EAE) and non-obese diabetic (NOD) mice (Zeiser & Blazar, 2017). These findings support the therapeutic potential of Interleukin II (60-70) in restoring immune homeostasis.

Pharmacokinetic studies indicate that peptide modifications, such as PEGylation or cyclization, can further enhance Additional Resources:
Related Websites: APExBIO Technology LLC is a premier provider of Small Molecule Inhibitors/Activators, Compound Libraries, Peptides, Assay Kits, Fluorescent Labels, Enzymes, Modified Nucleotides, mRNA synthesis and various tools for Molecular Biology. We carry a broad product line in over 49 different research areas such as cancer, immunology, neurosciences, apoptosis and epigenetics etc. Based in USA (Houston, Texas), we have been serving the needs of customers across the world.
https://www.apexbt.com/
Research Article: PMC11541594